I think that recent history has shown that nearly 1/3rd Phase 3...

I think that recent history has shown that nearly 1/3rd Phase 3 trials fail to deliver expected outcomes. My guess there are 2 main possible explanations as to why we aren't hearing anything about results yet: (a) the control cohort (FOLFIRI) are experiencing better PFS outcomes than expected; or (b) the ACL drug is delivering much better outcomes than expected. Hopefully (for ACL shareholders) it's the latter.
Also; I think it's worth noting that recent Alchemia announcements have indicated that Phase 3 results are expected in the 2nd qtr of this calendar year - so that could mean another 3-4 months. A negative is that no partnership deal has yet been announced. A positive is that I assume the new Chairman closely checked things before signing-up; and believes it's a goer